- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03568058
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
A Phase 1b Safety and Feasibility Study of Personalized Immunotherapy in Adults With Advanced Cancers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to determine if it is possible to make and administer safely a 'personalized' vaccine to treat patients that have been diagnosed with advanced cancer and are not candidates for curative therapy.
This 'personalized' vaccine will use information gained from specific characteristics of your own cancer. It is known that cancer has mutations (changes in genetic material) that are specific to an individual and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune (protective) responses, which may help your body fight any tumor cells that could cause your cancer to come back in the future. The study will examine the safety of the vaccine when given at several time points and will examine your blood cells for signs that the vaccine induced an immune response.
The personalized vaccine will be given in combination with an anti-PD1 antibody, pembrolizumab, which is used with the intention to increase anti-cancer immunity (protection). Pembrolizumab is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the "brakes" on the immune system are released and T cells are able to kill cancer cells better.
This personalized vaccine is considered experimental because this is not an FDA approved therapy for cancer.
Pembrolizumab is FDA approved for the treatment of melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), classical Hodgkin lymphoma (cHL), primary mediastinal large b-cell lymphoma (PMBCL), urothelial carcinoma, tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma (cSCC), triple-negative breast cancer (TNBC), microsatellite instability-high (MSI-H) or mismatch repair deficient cancer, microsatellite instability-high or mismatch repair deficient colorectal cancer (CRC), gastric cancer, esophageal cancer, cervical cancer, and hepatocellular carcinoma (HCC), merkel cell carcinoma (MCC), renal cell carcinoma (RCC), endometrial carcinoma. Pembrolizumab is considered experimental (investigational) for the treatment of all other cancer types.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92103
- UCSD Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Histologically or cytologically documented incurable solid tumor [excluding lymphoma].
- Measurable disease as defined by RECIST 1.1
- Progressed on or be intolerant to therapies that are known to provide clinical benefit.
- Non-measurable disease by RECIST 1.1 and high-risk (>50% over 5 years) of mortality
- At least one tumor site accessible for biopsy.
- Adequate organ function
- Women of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.
Exclusion Criteria
- Currently receiving or has received another anti-cancer therapy within 4 weeks prior to first dose of vaccine study treatment.
- Currently receiving or has received PD1/PDL1 inhibitor immunotherapy within 4 weeks prior to first dose of study treatment.
- Currently receiving or has received anti-PD1 or anti-CTLA4 treatment during the vaccine preparation period.
- Receiving TNF pathway inhibitors, PI3 kinase inhibitors, systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the first dose of study medication.
- Received an investigational agent within 28 days prior to the first dose of study drug.
- Untreated brain metastases; individuals with treated and stable metastases are eligible. Eligible subjects should have recovered from the acute effects of radiation therapy or surgery prior to study entry, have discontinued corticosteroid treatment for brain metastases for at least 4 weeks and are neurologically stable for 8 weeks (confirmed by MRI) prior to administration of experimental therapy
- Has known history of Human Immunodeficiency Virus (HIV).
- Received a diagnosis of hepatitis B or hepatitis C for which there is no clear evidence of natural immunity, immunity subsequent to vaccination, or successful eradication of the virus following antiviral therapy (individuals who are hepatitis C antibody positive may be enrolled if negative viral load confirmed).
- History of autoimmune disease including: inflammatory bowel disease (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis (e.g. Wegener's granulomatosis); central nervous system or motor neuropathy considered of autoimmune origin (e.g. Guillain-Barré syndrome, myasthenia gravis, multiple sclerosis). Individuals with vitiligo, Sjogren's Syndrome, interstitial cystitis, Graves' or Hashimoto's Disease, celiac disease, DM1, or hypothyroidism stable on hormone replacement will be allowed with Study Medical Monitor's approval.
- Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
- History of receiving a solid organ transplant or allogeneic bone marrow transplant.
- Major surgical procedure within 28 days prior to the first dose of study drug.
- If female, pregnant or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: vaccine and anti-PD-1
personalized vaccine and anti-PD-1 administered concurrently at the start of study therapy
|
Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
Other Names:
|
Experimental: anti-PD1 before vaccine
anti-PD-1 antibody for 6 weeks followed by personalized vaccine therapy
|
Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
Other Names:
|
Experimental: anti-PD1 and vaccine
anti-PD-1 antibody followed by personalized vaccine therapy
|
Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
Other Names:
|
Experimental: vaccine
personalized vaccine therapy
|
Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Quantitative frequency of TCR
Time Frame: 1 year
|
1 year
|
Number of Participants with Treatment-related Adverse Events
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response
Time Frame: 1 year
|
RECIST 1.1
|
1 year
|
Progression-free survival (PFS)
Time Frame: 1 year
|
Duration of time from start of study treatment until objective tumor progression or death.
|
1 year
|
Time to Progression
Time Frame: 1 year
|
Duration of time from start of study treatment until objective tumor progression.
|
1 year
|
Overall Survival
Time Frame: 1 year
|
Duration of time from start of study treatment to death
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Erza Cohen, MD, University of California, San Diego
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 180410
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
AstraZenecaTerminatedCancer | Advanced Solid Tumors | Advanced Solid MalignanciesUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
Clinical Trials on personalized vaccine
-
Xuanwu Hospital, BeijingBeijing Neoantigen Biotechnology CompanyRecruitingMalignant Glioma | Recurrent GliomaChina
-
Guangdong 999 Brain HospitalJinan University Guangzhou; Beijing Tricision Biotherapeutics Inc; Trinomab Biotech...CompletedBrain Cancer | Neoplasm MetastasesChina
-
Anda Biopharmaceutical Development (Shenzhen) Co...Recruiting
-
Changhai HospitalStemirna TherapeuticsUnknownPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Colorectal Adenocarcinoma | Advanced Esophageal Squamous CarcinomaChina
-
Stemirna TherapeuticsThe First Affiliated Hospital of Zhengzhou UniversityRecruitingEsophageal Cancer | Non Small Cell Lung CancerChina
-
Washington University School of MedicineSusan G. Komen Breast Cancer FoundationCompletedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast CancerUnited States
-
Jaime Leandro Foundation for Therapeutic Cancer...Enrolling by invitationCancer | Solid TumorUnited States
-
Ruijin HospitalRecruitingAdvanced Pancreatic CancerChina
-
Frame Pharmaceuticals B.V.University Medical Center Groningen; Erasmus Medical Center; The Netherlands... and other collaboratorsNot yet recruiting
-
Ruijin HospitalShanghai Xinpu BioTechnology Company LimitedRecruitingAdvanced Solid TumorChina